Is Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Harmony Biosciences Holdings, Inc. at current levels.
A cash-gushing rare disease franchise trading at 6x forward earnings while the market waits for pitolisant to escape narcolepsy.
Where HRMY is headed
Harmony spent the last five years being valued as a one-drug company on borrowed time. WAKIX loses exclusivity in 2030, the story goes, so pay 6x earnings and no more. That framing is about to break. By late 2027, Harmony should have Phase 3 readouts for pitolisant in Prader-Willi Syndrome, a real shot at FDA approval for ZYN-002 in Fragile X, and an orexin 2 agonist (BP1.15205) moving through the clinic in the same category where Takeda and Centessa are being valued as multi-billion-dollar programs on nothing but early data. Any two of those three land, and the WAKIX-cliff narrative dies.
Read the full Compass Direction on HRMY
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $39.93).
See the full HRMY analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Harmony Biosciences Holdings, Inc. at current levels. A cash-gushing rare disease franchise trading at 6x forward earnings while the market waits for pitolisant to escape narcolepsy.
What is HRMY's Compass Score?
Harmony Biosciences Holdings, Inc. scores 88/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for HRMY?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the HRMY page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.